	US 12,419,919 B2
	Probiotic formulations for the treatment and alleviation of metabolic and oxidative stress, inflammation and neurodegeneration
Susan Westfall, Montreal (CA); and Satya Prakash, Montreal (CA)
Assigned to Proviva Pharma Inc., Montreal (CA)
Filed by Proviva Pharma Inc., Montreal (CA)
Filed on Jan. 14, 2024, as Appl. No. 18/412,561.
Application 18/412,561 is a division of application No. 16/969,759, granted, now 11,992,510, previously published as PCT/CA2019/000018, filed on Feb. 12, 2019.
Claims priority of provisional application 62/629,832, filed on Feb. 13, 2018.
Prior Publication US 2024/0390435 A1, Nov. 28, 2024
Int. Cl. A61K 35/747 (2015.01); A23L 33/135 (2016.01); A61K 35/00 (2006.01); A61K 35/742 (2015.01); A61K 35/745 (2015.01)

CPC A61K 35/745 (2013.01) [A23L 33/135 (2016.08); A61K 35/747 (2013.01); A61K 2035/115 (2013.01)]

6 Claims

1. A probiotic formulation manufactured or formulated as an edible material, drink or foodstuff, the formulation comprising a synergistic combination of three isolated bacterial strains, wherein the three isolated bacterial strains are Lactobacillus fermentum NCIMB 5221, Lactobacillus plantarum NCIMB 8826, and Bifidobacterium longum NCIMB 702255.